Article Text

Download PDFPDF
Systemic treatment policies in ovarian cancer: the next 10 years
  1. J. J. Biagi* and
  2. E. A. Eisenhauer
  1. * Kingston Regional Cancer Centre, Kingston, ON, Canada
  2. NCIC Clinical Trials Group, Queen's University, Kingston, ON, Canada
  1. Address correspondence and reprint requests to: Dr James J. Biagi, MD, FRCP (C), Academic Medical Oncologist, Kingston Regional Cancer Centre, 25 King Street West, Kingston, ON Canada, K7L 5P9. Email: jim.biagi{at}


Over the past two decades, the development of treatment policies and practice standards has become formalized. In ovarian cancer, most attention has been focused on the development of policies for front-line systemic treatment, using survival as the major outcome that should drive change. This review summarizes the evidence that supported the emergence of paclitaxel–carboplatin as a widely used standard of care for front-line therapy and some of the contradictory data from randomized studies. Furthermore, recently completed or ongoing randomized studies of the addition of a third cytotoxic agent to paclitaxel–carboplatin are summarized. Finally, some novel noncytotoxic approaches are discussed. New standards of care and treatment policies in the next decade will be based on high-quality evidence of improved survival from controlled studies. Many such trials are now ongoing or planned.

  • evidence-based medicine
  • ovarian cancer
  • review
  • systemic therapy

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.